China: Life Sciences, Biotechnology & Nanotechnology

China's pharmaceutical and life sciences regulatory landscape underwent significant transformation in 2026, with major policy updates spanning drug approval processes, medical device quality standards, and healthcare facility management. The National Medical Products Administration introduced priority review pathways for chemical APIs and updated cosmetics registration requirements, while new medical device production standards took effect nationwide.

生物安全及人类遗传资源管理是医药企业开展研发、临床试验、生物制品生产及跨境科研合作时需要关注的重要合规领域。本文结合医药企业的主

China has rapidly emerged as a dominant force in early-stage biotech innovation, challenging traditional U.S. hubs like San Francisco and Boston through faster development timelines, lower clinical trial costs, and aggressive government support. As deal volume between Western biopharma companies and Chinese biotechs surges dramatically, industry leaders must navigate the complex balance between accessing China's growing scientific contributions and managing heightened geopolitical tensions and U.S. regulato

A Paris roundtable examined China's transformation into a biotechnology powerhouse and the strategic opportunities this creates for European life sciences companies and investors. Industry leaders discussed how to structure cross-border partnerships that leverage Chinese innovation and development speed while navigating intellectual property protection, regulatory frameworks, and evolving geopolitical considerations.

広州市の創薬ベンチャー、広東衆生睿創がWIPOグローバル・アワード2026のファイナリストに選出され、中国から計6社が入選。また、広東邦普循環科

In recent years, China's biotech scene has risen in prominence with its innovative R&D and promising pipelines commanding big pharma's attention. In this blog, we take a look at this trend, which sees China-related deals and investment continuing to flow, as well as the recent developments in the US, with draft legislation being proposed that seeks to impose restrictions which would impact transactions between US pharma companies and Chinese biotechs. 

日前，市场监管总局、国家网信办联合发布...

On January 16, 2026, the State Council of the People's Republic of China promulgated the revised Regulations for the Implementation of the Drug Administration Law (the "Implementing Regulations")...

This China Newsletter provides an overview of key developments in the following areas...